Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
EMERGENT BIOSOLUTIONS, Inc. Add to My Watchlist (NYSE: EBS) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     EMERGENT 13.81 -0.09 (-0.65%) 24,600
2273 Research Boulevard
Suite 400
Rockville, MD 20850 US
301 795-1800
301 795-1899 fax
www.emergentbiosolutions.com
CEO Fuad El-Hibri
Auditor Ernst & Young LLP
Exchange Traded NY
ISIN Number US29089Q1058
CIK Number 1367644
NAICS Code 325412
Business Summary
A biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the bodys immune system to prevent or treat disease.
Number of Employees 587
Share Fundamentals
Market Cap 425.64M
Shares Outstanding 30.80M
Float 17.13M
Short Interest 835.25K
Financial Strength
Revenue (TTM) $216,732,000
Earnings (TTM) $25,827,000
Quick Ratio 2.7:1
Current Ratio 3.4:1
Total Debt/Equity 0.17:1
Profitability
Gross Margin 83.3%
EBITDA Margin 19.4%
Profit Margin 16.4%
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Daily Market Updates provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs